Translation and validation of Persian version of sexual function: vaginal changes questionnaire (SVQ) for women with gynecologic cancers

Raziyeh Maasoumi1,2, Farinaz Rahimi3 and Somayyeh Naghizadeh4*

Abstract

Background: Changing in the sexual function is an important condition in women with gynecological cancers. A valid and reliable questionnaire is required to assess this condition. The aim of this study was to translate and validate the Persian version of the Sexual-Vaginal Function Changes Questionnaire (SVQ) in women with gynecologic cancers.

Methods: This methodological study with a psychometric design was conducted on 250 women with gynecologic cancers, who visited public and private medical centers in Tehran to receive follow-up services. Convenience sampling was conducted from April 2019 to May 2020. First, the Persian version of the Sexual Function-Vaginal Changes Questionnaire was developed and then, psychometric properties such as content validity, face validity, construct validity and criterion validity were assessed. Reliability of the instrument was assessed by Cronbach's alpha coefficient.

Results: Mean age of participants was 53.3 ± 11.8 and mean score of SVQ was 63.0 ± 9.1 in the possible range of 26–104. Content validity was tested through qualitative method and six items were revised as suggested by the expert panel. Cronbach's alpha coefficient was 0.71 for the whole questionnaire and it was 0.93, 0.92, 0.89, 0.78, 0.88 and 0.78 for the 6 subscales, respectively, which shows the optimal internal consistency. Results of exploratory factor analysis revealed six factors as (1) intemacy and sexual interest, (2) arousal, (3) changes in intemacy and sexual interest after cancer, (4) vaginal changes after cancer, (5) vaginal bleeding during coitus, (6) and sexual worry and dissatisfaction after cancer. explained 70.09% of the variance observed. Criterion validity test of the questionnaire showed a significant correlation between the total SVQ scores and the total Female Sexual Function Index (FSFI) scores as well as between SVQ dimensions and dimensions of FSFI (P < 0.001).

Conclusions: The findings from this study indicated that the Persian version of the SVQ is a valid and reliable instrument to assess sexual function-vaginal changes in women with gynecologic cancers.

Keywords: Gynecologic cancer, Sexual function, Vaginal function, Validity, Reliability

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Gynecologic cancer (GC) is any cancer that starts in a woman's reproductive organs [1]. Gynecologic cancers account for 16% of female malignancies worldwide [2]. GC treatments include surgery, chemotherapy, radiotherapy, or combination therapy. With medical advances, the number of GC survivors has increased [3]. With

*Correspondence: somayyehnaghizadeh86@gmail.com

4 Department of Midwifery, Faculty of Medical Sciences, Tabriz Medical Sciences, Islamic Azad University, Tabriz, Iran

Full list of author information is available at the end of the article
improved effectiveness of cancer treatments, the number of GC survivors has been reported to exceed 1 million in 2016 [4].

The National Comprehensive Cancer Network (NCCN) provided guidelines for cancer survivors. In these guidelines for sexual function, health care providers are recommended to ask people about their sexual function at regular intervals [5]. Despite increased life expectancy in these women, gynecologic cancers may affect many aspects of women’s health, including sexual function [6] and quality of life of GC survivors [3]. Sexual health is, therefore, considered as one of the components of quality of life and an important aspect in GC treatments [7, 8]. In their study, Olivia et al. revealed that women with ovarian cancer experience a lower quality of life and a higher rate of sexual dysfunction and distress [9]. Therefore, cancer and cancer treatments affect physical and mental function, which can significantly affect women’s intimate relationship with their sex partner [10].

GC Survivors experience a wide range of sexual concerns following diagnosis and treatment [11, 12]. Sexual dysfunction is associated with treatment outcomes of surgery, radiation therapy, chemotherapy, and hormone therapy, as well as cancer itself [13, 14]. These women reported some problems including decreased sexual desire, vaginal dryness and/or dyspareunia, problems with sexual arousal and/or orgasm, and low sexual satisfaction [12, 15]. In addition to the physiological impacts, these women suffered from a wide range of psychological consequences such as loss of femininity, negative body image, and psychological distress [16]. Cancer and cancer treatment may even lead to a cessation of sexual activity [17]. In the US, Blake et al. (2017) conducted a study on women with GC using FSFI and revealed that women undergoing chemotherapy suffered from post-cancer treatment sexual dysfunction [18].

Sexual dysfunction is reported in most patients visiting for cancer treatment follow-up care; therefore, health care providers should evaluate their sexual performance [19]. Various tools have been used so far to assess women’s sexual health such as Female Sexual Dysfunction Index (FSFI), Quality of Life—Cancer Survivors (QOL-Cs), Questionnaire on Screening for Sexual Dysfunction (QSD), and The Functional Assessment of Cancer Therapy—Endometrial (FACT-En). The FSFI measures general aspects of female sexual dysfunction; it has been developed and validated for normal women with sexual dysfunction and does not cover cancer and cancer treatment [20]. QOL-Cs assess various aspects of quality of life in cancer survivors; however, it covers all types of cancers [21] not just GC. QSD examines sexual dysfunction and different stages of sexual cycle [22]. None of these inventories specifically assess sexual function in women with GC. Sexual-Vaginal Function Changes Questionnaire (SVQ) was first developed and psychometrically tested by Jensen et al. (2004) in Denmark to assess post-GC treatment sexual function [20]. It was psychometrically tested by Chow et al. (2010) in China [7].

Cervical cancer, ovarian cancer and uterine cancer are the second, eighth and eleventh most common cancers among Iranian women. The first report by Iran Cancer Research Center indicated that the incidence of these cancers in Iran is 4.8, 4.6 and 2.6, respectively [23]. Given the high prevalence of these cancers among Iranian women and increased life expectancy in them due to the improved and effective cancer treatments, the number of Iranian GC survivors is increasing. Therefore, sexual complications and disorders following cancer treatments have also increased in these women [24]. To study these problems, a valid and reliable measure is required. Therefore, due to the lack of questionnaire and these problems associated GC survivors, the aim of this study was to translate and validate the Persian version of the Sexual-Vaginal Function Changes Questionnaire in Persian women with gynecologic cancers.

Methods
Type of study and participants
This methodological study with a psychometric design was conducted on women with gynecologic cancers using convenience sampling from April 2019 to May 2020. The research setting was 4 medical centers in Tehran (Be’sat and Loghman hospitals as a public centers and Roshana and Kimia oncology clinics as a private centers). Convenience sampling was used to select medical centers from different districts in Tehran.

Inclusion criteria were literacy for reading and writing, being married, and sexually active (having any type of sexual relationship, including a range of activities such as foreplay, penetration and afterplay) within the last 6 months. All of these criteria were provided using self-report. The other inclusion criteria were definitive diagnosis of endometrial, cervical or ovarian cancer and in a state of recovery period based on the medical records. Exclusion criteria were suffering from or the history of known mental illnesses that affect sexual function, experiencing an unfortunate event in the past 3 months before the start of the study (death of loved ones etc.) and having extramarital affairs of each couple. All of exclusion criteria were provided using self-report. It is necessary to explain that the data were collected using closed-ended questions when women’s physical and mental conditions were stable. In order to estimate the sample size in this study, the sample size should be 10 times of the number of items in the instrument [25]. Thus, a sample of 240 was
obtained and considering a 10% sample loss, a total sample size of 250 was calculated.

Sampling
After receiving the code of ethics from the Joint Organizational Ethics Committee of the School of Nursing and Midwifery and the School of Rehabilitation of Tehran University of Medical Sciences (Code: IR.TUMS.FNM.REC.1397.208) and presenting a letter of introduction to the authorities of the relevant medical centers, the relevant permit was obtained for sampling. All eligible women with endometrial, cervical and ovarian cancers who were willing to participate entered the study and the objectives were explained to them. Before starting the study, the participants were provided with necessary explanations about the objectives and method of the study, voluntary participation, respect for privacy, confidentiality and the right to refrain from any data collection stage. As a compensation, the samples informed about that those who wished to receive sexual education or counseling about their sexual concerns or problems related to the GCs, they could be contact to the researcher team after participate in the study. They were assured that there was no need to write their first and last name and that all their information would remain confidential with the researcher. Informed written consent was obtained from participants. This study was conducted in two phases. First, the Persian version of SVQ was developed and then, it was psychometrically tested.

Data collection tools
Three inventories, including demographic profile scale, SVQ and the FSFI were used to collect data.

Persian version of sexual function -vaginal changes questionnaire (SVQ)
Jensen et al. (2004) first developed and conducted psychometric testing on SVQ in Denmark [20] to investigate post-GC treatment sexual function. This questionnaire consists of 27 items and 5 subscales, including intimacy (IN), global sexual satisfaction (GS) and sexual interest (SI). All participants answered the scale regardless of having the spouse available or sexual function. Vaginal changes (VC) and sexual function (SF) were answered only by sexually active patients. Then, Chow et al. (2010) conducted psychometric testing of this scale in China [7]. Psychometric testing of the instrument in this study was based on the translation and adaptation process provided by the World Health Organization [26].

Translation
After obtaining permission from the original developer of the questionnaire, it was translated into Persian in four stages. First, the questionnaire was Forward Translation by two Persian-speaking English translators. Then, the translated versions were compared by the expert panel in the presence of two translators and a common translation was agreed upon. In the third stage (backward translation), two English-speaking translators who were fluent in Persian and had not previously seen the English version of the questionnaire were asked to back-translate the Persian version of the questionnaire into English. In the last phase, Pre-testing and cognitive interviews were conducted to measure the clarity of translated version and incomprehensible items were marked and revised. The translated version was given to 10 applicants who met the inclusion criteria. Their views about each item were asked through personal interviews, and the items that were not understood were identified and the necessary changes were made. Finally, the final Persian version was approved.

Validity
Content validity, face validity, construct validity and criterion validity were used to validate SVQ.

Content validity
Content validity was tested through qualitative method. In the qualitative content analysis, the author gave the questionnaire to 10 specialists in oncology, sexual and reproductive health, health promotion, health psychology and social medicine and the necessity, clarity and simplicity of the instrument were examined.

Face validity
To conduct face validity analysis, it was tried to adopt fluent writing style with appropriate wording. To this purpose, the translated questionnaire was presented to 15 eligible women and they were asked about the simplicity, comprehensibility and clarity of the items to evaluate qualitative face validity. To test quantitative face validity, a 5-point Likert scale was used (Very Important = 5, Important = 4, Moderately Important = 3, Slightly Important = 2, Not Important = 1) and the impact score was asked. Impact score of 1.5 or higher approved quantitative face validity.

Construct validity
Construct validity determines whether a questionnaire can meet the objectives of the study [27], and exploratory factor analysis indicates whether the instrument items are properly arranged. To measure construct validity, the correlation of the items before factor analysis should be examined using Bartlett’s test and KMO index and this index should not be less than 0.5 [28]. To examine construct validity, exploratory factor analysis with
orthogonal varimax rotation was used by maximum likelihood method in SPSS 22 with a factor loading greater than 1 and load factor larger than 0.4.

**Criterion validity**
The Persian version of FSFI was used in this study to test criterion validity of SVQ. To this purpose, both scales were given to participants and data were collected simultaneously. The Persian version of the standard FSFI developed by Rosen et al. [29] has 19 items in 6 dimensions, including sexual desire (2 items), arousal (4 items), lubrication (4 items), orgasm (3 items), sexual satisfaction (3 items) and pain (3 items).

**Reliability**
To determine the reliability, the Cronbach’s alpha coefficient was measured for the whole questionnaire and its subscales.

**Results**
Mean ± standard deviation of women’s age was 53.3 ± 11.8. Of participants, 28% had elementary education and only 20.4% had academic degrees. Two-third of participants (66.4%) were housewives. Mean ± standard deviation of length of marriage was 31.1 ± 16.4. Mean ± standard deviation of duration of cancer was 21.2 ± 20.6 months and nearly half of the participants (46.8%) were diagnosed with grade II cancer. Demographic data and clinical information of participants are shown in Table 1.

**Content validity**
Content validity was tested through qualitative method and six items were revised as suggested by the expert panel in the qualitative content validity assessment.

**Face validity**
Results of qualitative face validity assessment by end users of the questionnaire indicated the connection and fitness of the items with the subject under study, the correct understanding of the items by the respondents and the lack of ambiguity or difficulty in understanding the items. Results of qualitative face validity assessment showed an impact score larger than 1.5.

**Construct validity**
Results of Kaiser–Meyer–Olkin (KMO) test showed the sampling adequacy for exploratory factor analysis (KMO = 0.868). Bartlett’s test of sphericity with $X^2 = 6327.442$, $p < 0.001$ indicated that the correlation between items is large enough to perform maximum likelihood. The results showed six factors explained

| Table 1 | Demographic characteristics and clinical information of the participants (n = 250) |
|---------|----------------------------------------------------------------------------------|
| Number (Percent) | Characteristic |
| Age (Year) | M ± SD = 53.3 ± 11.8 |
| 29–39 | 83 (33.2) |
| 40–49 | 109 (43.6) |
| 50–69 | 58 (23.2) |
| Education | |
| Elementary | 70 (28.0) |
| Secondary | 33 (13.2) |
| Diploma | 96 (38.4) |
| University | 51 (20.4) |
| Job | |
| Housewife | 166 (66.4) |
| Working at home | 43 (17.2) |
| Working outside the home | 41 (16.4) |
| Husband’s age | M ± SD = 53.3 ± 11.8 |
| 30–50 | 91 (36.4) |
| 51–70 | 113 (45.2) |
| 71–90 | 46 (18.4) |
| Husband’s education | |
| Elementary | 71 (28.4) |
| Secondary | 56 (23.6) |
| Diploma | 64 (26.5) |
| University | 56 (22.4) |
| Husband’s job | |
| Unemployed | 62 (24.8) |
| Employee | 104 (41.6) |
| Employee | 103 (41.2) |
| Duration of marriage (year) | M ± SD = 31.1 ± 16.4 |
| 10 ≥ | 30 (12.0) |
| 11–30 | 106 (42.4) |
| 31–50 | 73 (29.2) |
| 50 < | 41 (16.4) |
| Contraception | |
| Menopause | 146 (58.4) |
| Withdrawal | 29 (11.6) |
| Condom | 46 (18.4) |
| Hysterectomy | 29 (11.6) |
| Duration of cancer (Month) | M ± SD = 21.2 ± 20.6 |
| 12 > | 114 (45.6) |
| 12–24 | 74 (29.6) |
| 25–36 | 28 (11.2) |
| 36 < | 34 (13.6) |
| Grade of cancer | |
| 1 | 66 (26.4) |
| 2 | 117 (46.8) |
| 3 | 57 (22.8) |
| 4 | 10 (4.0) |
| Treatments received | |
| Surgery | 110 (44) |
| Chemotherapy | 15 (6) |
70.09% of the variance (Table 2). In the 26-item version, factor loadings were named as follows after rotation:

- Factor 1, intimacy and sexual interest, including 8 items (1, 2, 3, 5, 6, 15, 16 and 17)
- Factor 2, arousal, including 5 items (7, 11, 11a, 12 and 12a)
- Factor 3, changes in intimacy and sexual interest after cancer, including 4 items (18, 19, 20, and 21)
- Factor 4, vaginal changes after cancer, including 4 items (14, 22, 23, and 24)
- Factor 5, vaginal bleeding during coitus, including 2 item (13 and 13a)
- Factor 6, sexual worry and dissatisfaction after cancer, including 3 items (8, 9, 10)

It is worth mentioning that item 14 was loaded on factors 2 and 4 and due to its compliance with item 2, it was moved there. Finally, 6 factors were explained, namely (1) intimacy and sexual interest, (2) arousal, (3) changes in intimacy and sexual interest after cancer, (4) vaginal changes after cancer, (5) vaginal bleeding during coitus, (6) and sexual worry and dissatisfaction after cancer. The results of the structural validity based on maximum likelihood analysis are shown in Table 3. In addition, the distribution of factors explained by the exploratory factor analysis in the scree plot is shown in Fig. 1.

### Criterion validity
Mean ± standard deviation of sexual—vaginal function changes (SVQ) was 62.9 ± 9.1 (in the possible range of 26–104), mean ± standard deviation of intimacy and sexual interest was 23.1 ± 6.2 (in the possible range of 8–41), arousal 10.5 ± 5.6 (in the possible range of 3–20), change in intimacy and sexual interest after cancer 7.5 ± 2.2 (in the possible range of 4–12), vaginal changes after cancer 7.9 ± 1.3 (in the possible range of 4–13), vaginal bleeding during coitus 2.4 ± 1.9 (in the possible range of 1–8), and Sexual worry and dissatisfaction after cancer 11.3 ± 2.9 (in the possible range of 3–18). The Persian version of FSFI was used in this study to test criterion validity of SVQ. There was a significant correlation between total SVQ scores and total FSFI scores and as well as between SVQ dimensions and dimensions of FSFI ($P < 0.001$) (Table 4).

### Reliability
Reliability of the instrument was assessed by Cronbach’s alpha coefficient. Cronbach’s alpha coefficient was 0.71 for the whole questionnaire and it was 0.93, 0.92, 0.89, 0.78, 0.88 and 0.78 for the 6 subscales, respectively, which shows the optimal internal consistency (Table 5).

### Discussion
This study was conducted for the first time in Iran to translate and validate the Persian version of the sexual function—vaginal Changes Questionnaire (SVQ) for patients with GC. Validation of the Persian version of the SVQ proved it a valid and dedicated instrument to assess sexual function—vaginal changes in Iranian women with gynecologic cancers. Cronbach’s alpha coefficient and internal consistency coefficient were acceptable with good reliability and stability for the questionnaire. In addition, there was reasonable qualitative content validity of this instrument.

SVQ was first developed and psychometrically tested by Jensen et al. in Denmark to assess post-GC treatment.
sexual function [20]. Results of their study found SVQ a reliable and valid scale [20]. Then, in 2010, Chow et al. conducted psychometric testing on this questionnaire and found SVQ a dedicated, reliable and applicable scale to assess sexual function in Chinese patients [7].

In this study, Cronbach’s alpha coefficient was 0.71 for the Persian version of SVQ. Since it was larger than 0.7, internal consistency of the scale was approved. It was in the range of 0.78–0.93 for subscales which complied with the Cronbach’s alpha coefficient obtained in the study by Jensen et al. for subscales (0.76–0.83) [20]. In the study by Chow et al. [7], internal consistency for the Chinese version of SVQ was 0.87 using Cronbach’s alpha which shows its high validity. Cronbach’s alpha coefficient was 0.64–0.88 for subscales which complied with this study.

The original SVQ consisted of two sections. The first section was for all patients (regardless of the spouse being available and sexual activity) with three subscales of intimacy, sexual desire and sexual satisfaction; the second section was for sexually-active patients with two more subscales in addition to the previous ones including vaginal changes and sexual function [20]. In the present study, given the principles of cultural adaptation and considering that sexual relations are legal in the context of marriage, being sexually active was considered as one of the inclusion criteria. Therefore, only sexually-active women were included in the study. The basis of translation and psychometric analysis of the Persian version of the SVQ was therefore the second structure of the main instrument proposed by Jensen et al. (2010) [20]; results

Table 3  Factor loading matrix for patterns identified in the SVQ questionnaire

| Items                                                                 | Factor loading |
|----------------------------------------------------------------------|---------------|
|                                                                      | Factor1 | Factor2 | Factor3 | Factor4 | Factor5 | Factor6 |
| 3. Have you had any interest in sexual relations?                     | .881    | -.094  | 237     | -.040  | -.057   | -.066   |
| 16. Have you reached orgasm?                                         | .798    | -.302  | .083    | -.283  | -.030   | .055    |
| 9. How satisfied or dissatisfied have you been with your sex life/lack of sex life | .764    | -.181  | .196    | -.110  | -.102   | .482    |
| 17. Did you feel relaxed after having sex?                           | .757    | -.181  | .053    | -.191  | -.140   | .198    |
| 5. Has your partner wanted to have sexual relations?                 | .754    | -.106  | .005    | -.117  | -.026   | .009    |
| 6. Have you had sexual relations?                                     | .738    | -.205  | .068    | -.042  | -.007   | .164    |
| 1. Have you been interested in close physical contact (a kiss and a cuddle)? | .735    | -.240  | .405    | .110   | -.044   | -.138   |
| 10. How satisfied or dissatisfied have you been with your appearance? | .718    | -.178  | .192    | -.166  | -.062   | .503    |
| 15. Were you able to complete sexual intercourse?                     | .706    | -.264  | .226    | .039   | -.047   | -.119   |
| 2. Have you had close physical contact with your family and close friends? | .675    | -.056  | .312    | .165   | -.055   | .022    |
| 7. Did your partner have difficulty achieving an erection?            | -.532   | -.373  | -.086   | .005   | -.026   | .251    |
| 11a. If yes, has it bothered you?                                    | -.317   | .851   | -.046   | .183   | .188    | -.069   |
| 12a. If yes, has it bothered you?                                    | -.263   | .847   | .003    | .275   | .159    | -.084   |
| 11. Did you feel that your vagina was dry during intercourse?        | -.388   | .794   | -.015   | .258   | .192    | -.044   |
| 12. Have you had any pain during intercourse?                        | -.385   | .724   | .024    | .362   | .229    | -.055   |
| 18. Has your interest in close physical contact changed since you were diagnosed with cancer? | .097    | .026   | .961    | .016   | .098    | .008    |
| 19. How much close physical contact do you have with your family and close friends compared to before you were diagnosed with cancer? | .115    | .021   | .915    | .080   | .096    | -.014   |
| 20. Has your interest in sexual relations changed since you were diagnosed with cancer? | .286    | .078   | .766    | -.077  | .063    | .008    |
| 21. Has your partner’s interest in sexual relations changed since you were diagnosed with cancer? | .292    | -.009  | .552    | -.333  | -.061   | .082    |
| 23. Do you feel that the size of your vagina has changed since you were diagnosed with cancer? | .053    | -.117  | .024    | -.775  | .083    | .065    |
| 24. Has the pain you experience during intercourse changed since you were diagnosed with cancer? | -.039   | .182   | -.053   | .713   | .130    | -.225   |
| 22. Has the dryness of your vagina changed compared to before you were diagnosed with cancer? | .082    | .276   | -.263   | .606   | .158    | -.057   |
| 14. Did you feel that intercourse was bothersome because your vagina felt too small? | -.226   | .368   | .099    | .590   | .219    | -.007   |
| 13. Have you experienced bleeding during intercourse?                | -.125   | .233   | .106    | .250   | .914    | -.133   |
| 13a. If yes, has it bothered you?                                    | -.062   | .327   | .053    | .252   | .750    | -.163   |
| 8. Has your sex life/lack of sex life made you worry?                | -.039   | .045   | -.038   | .228   | .201    | -.487   |

The symbol bold loading factors indicate the most significant number of factor loading in each dimension.
revealed 6 factors as (1) intimacy and sexual interest, (2) arousal, (3) changes in intimacy and sexual interest after cancer, (4) vaginal changes after cancer, (5) vaginal bleeding during coitus, (6) and sexual worry and dissatisfaction after cancer.

The first dimension of the Persian version of SVQ consists of the questions related with the close physical contact, interest in sexual relations, the ability to complete sexual intercourse, and achievement of orgasm. The second dimension consists of the questions related with the genital condition during sexual function like as difficulty to achieve an erection in partner, vaginal dryness, pain

Table 4: Mean (SD) SVQ dimensions and its relationship with FSFI dimensions

| Characteristic                                      | Mean (SD) | Obtainable range | Earned range | Relationship with FSFI r (p) |
|-----------------------------------------------------|-----------|------------------|--------------|------------------------------|
| 1. Intimacy and sexual interest                     | 23.1 (6.2)| 8–41             | 11–33        | 0.703 (P < 0.001)            |
| 2. Arousal                                          | 10.5 (5.6)| 3–20             | 3–20         | 0.511 (P < 0.001)            |
| 3. Change in intimacy and sexual interest after cancer | 7.5 (2.2)| 4–12             | 4–12         | 0.318 (P < 0.001)            |
| 4. Vaginal changes after cancer                     | 7.9 (1.3)| 4–13             | 5–11         | 0.220 (P < 0.001)            |
| 5. Vaginal bleeding during coitus                   | 2.4 (1.9)| 1–8              | 1–8          | 0.293 (P < 0.001)            |
| 6. Sexual worry and dissatisfaction after cancer    | 11.3 (2.9)| 3–18             | 3–17         | 0.625 (P < 0.001)            |
| Sexual-Vaginal Function Changes (SVQ)               | 62.9 (9.1)| 26–104           | 39–82        | 0.357 (P < 0.001)            |

Table 5: Reliability of the whole SVQ questionnaire and its subscales

| Number of items | Cronbach's alpha |
|-----------------|------------------|
| 1. Intimacy and sexual interest                     | 8                | 0.93             |
| 2. Arousal                                              | 5                | 0.92             |
| 3. Change in intimacy and sexual interest after cancer | 4                | 0.89             |
| 4. Vaginal changes after cancer                       | 4                | 0.78             |
| 5. Vaginal bleeding during coitus                     | 2                | 0.78             |
| 6. Sexual worry and dissatisfaction after cancer      | 3                | 0.78             |
| Sexual-Vaginal Function Changes (SVQ)                | 26               | 0.71             |
during intercourse and feeling of bothering with dryness and pain. The third dimension consists of the questions related with the changes in close physical contact and interest in sexual relations after cancer. The fourth dimension consists of the questions related with the vaginal changes after cancer specially in size, dryness, and pain during intercourse. The fifth dimensions of the Persian version of SVQ consists of the questions related with the vaginal bleeding during coitus and feeling of bothering with its experience. Finally, the sixth dimension consists of the questions related with the worry and dissatisfaction about appearance and lack of sexual life after cancer.

Comparing with the original version of SVQ, the first dimension of the Persian version can be explaining the first three dimensions of the original version of SVQ including intimacy (IN), global sexual satisfaction (GS), and sexual interest (SI). In addition, in the original version of SVQ, the dimensions of the vaginal changes (VC) and sexual function (SF) indicate all of changes in vagina and sexual function but in the Persian version, these dimensions were explored in the three constructs as arousal (the second dimension), vaginal changes after cancer (the fourth dimension), and vaginal bleeding during coitus (the fifth dimension). The last dimension of Persian version of SVQ can also be explain with the sexual interest area of the original version.

Comparing with the Chinese version of the SVQ and its Persian version showed that Chow et al’s study dataset be inappropriate because the Kaiser–Meyer–Olkin (KMO) value was less than 0.6 but, in our study, the KMO value was more than 0.8. However, Chow et al’s reported factor analysis supported the items applicable to sexually active respondents, clustered together into 2 hypothesized scales: vaginal changes (VC) and sexual function (SF) and they declared that their findings supported the results of the original study [7]. According to our results of the factor analysis, also, the dimensions of the original SVQ were supported with some changes that discussed above mentioned.

The results of criterion validity in the present study showed that the significant correlation between dimensions and total SVQ scores and FSFI. It could be supported that the basic assumption of the development of SVQ by Jensen et al. that they drafted SVQ from FSFI. In addition, these results indicated that SVQ can be a good alternative tool to the FSFI in the patents with GCs because SVQ can be measure the sexual function as well as FSFI and also shows the changes caused by GCs in female sexual function.

Results of the study found this questionnaire a valid and reliable instrument to conduct surveys in oncology settings on Iranian women population. Because cervical cancer, ovarian cancer and uterine cancer are the second, eighth and eleventh most common cancers among Iranian women [23]. Given the high prevalence of these cancers among Iranian women and increased life expectancy in them due to the improved and effective cancer treatments, the number of Iranian GC survivors is increasing. Therefore, sexual complications and disorders following cancer treatments have also increased in these women [24]. So, the Persian version of SVQ has the potential to be used as a practical tool in clinical practice and research for assessing sexual function problems in Iranian as well as non-Iranian but Persian language gynecological cancer patients, to identify those in need of appropriate counseling or other forms of intervention [19]. One of the limitations of this study was the potential bias in answering the questions due to the sensitivity of the research topic. It was tried to eliminate it by assuring the confidentiality of information and completing questionnaires anonymously. Although the present study confirms the psychometric properties of the Persian version of SVQ but to increase generalizability findings from this study are needed research should be conducted using this tool throughout similar setting. The future research should also be examining the confirmation of the factors of questionnaire between different GCs groups of respondents.

Conclusion
The findings from this study indicated that the Persian version of the SVQ is a valid and reliable instrument to assess sexual function—vaginal changes in women with gynecologic cancers.

Abbreviations
SVQ: Sexual function and vaginal changes after gynecological cancer questionnaire; GC: Gynecologic cancer; NCCN: The National Comprehensive Cancer Network; FSFI: Female sexual function index; QOL-Cs: The quality of life-cancer survivors; QSD: Questionnaire on screening for sexual dysfunction; FACT-En: The functional assessment of cancer therapy-endometrial; IN: Intimacy; GS: Global sexual satisfaction; SI: Sexual interest; VC: Vaginal changes; SF: Sexual function; SD: Standard deviation.

Acknowledgements
This research has been supported by Tehran University of Medical Sciences & health Services grant to the contract number 40533. The author appreciates the Deputy of Research and Technology of Tehran University of Medical Sciences as well as efforts of the presidents, authorities and staff of public and private medical centers in Tehran.

Author contributions
RM and FR involved in the conception and design, acquisition of data, and drafting of the manuscript. SN (corresponding author) involved blinded analysis of the data, interpretation of data, and writing this manuscript. All authors gave their final approval of this version to be published.

Funding
This study was financially supported by the Tehran University of Medical Sciences.
Availability of data and materials
Datasets used and analyzed during this study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
All the procedures performed in this study that involved human subjects were in full compliance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval was obtained from the ethics committee Tehran University of Medical Sciences (IR. TUMS.FNM.REC.1397.208) to conduct the research. Written informed consent was obtained from all the participants before enrolment in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. 2 Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. 3 Department of Reproductive Health and Midwifery, Faculty of Medical Sciences, Tabriz Modares University (TMU), Tehran, Iran. 4 Department of Midwifery, Faculty of Medical Sciences, Tabriz Medical Sciences, Islamic Azad University, Tabriz, Iran.

Received: 28 April 2021 Accepted: 4 July 2022
Published online: 08 July 2022

References
1. Division of Cancer Prevention and Control, C.F.D.C.a.P. https://www.cdc.gov/cancer/gynecologic/basic_info/what-is-gynecologic-cancer.htm 2019.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBCAN 2012. Int J Cancer. 2015;136(5):359–86.
3. Lindau ST, Abramssohn EM, Matthews AC. A manifesto on the preservation of sexual function in women and girls with cancer. Am J Obstet Gynecol. 2015;213(2):166–74.
4. Miller KD, Siegel RL, Chun Chieh Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Ahmedin J. Cancer treatment and survivorship statistics: CA: A Cancer J Clin. 2016;66(4):271–89.
5. Melisko ME, Narus J.B. Sexual function in cancer survivors: updates to the NCCN guidelines for survivorship. J Natl Compr Canc Netw. 2016;14(5):685–9.
6. Wettergren L, Lungman L, Obel CM, Eriksson LE, Lampic C. Sexual dysfunction and fertility-related distress in young adults with cancer over 5 years following diagnosis: study protocol of the Fex-Can Cohort study. BMC Cancer. 2020;20(1):1–9.
7. Chow KM, So WKW, Chan CWH. Assessing sexual function amongst Hong Kong Chinese patients with gynecological cancer: TRANSLATION and validation of the Sexual Function-Vaginal Changes Questionnaire (SVQ). J Gynecol Cancer Res. 2010;7(4):230–3.
8. Guntupalli SR, Sheeder J, Ioffe Y, Tergas A, Wright JD, Davidson SA, Behbahkt K, Flink DM. Sexual and marital dysfunction in women with gynecologic cancer. Int J Gynecol Cancer. 2017;27(3):603–7.
9. Fischer CJ, Marquerie M, Brotto LA. Sexual function, quality of life, and experiences of women with ovarian cancer: a mixed-methods study. Sex Med. 2019;7(4):530–9.
10. Syme ML, Delaney E, Wachen JS, Gosian J. Sexual self-esteem and psychosocial functioning in military veterans after cancer. J Psychosoc Oncol. 2013;31(1):1–12.
11. Dixon DS, Suzin D, Mtlivenna S. Sexual health as a survivorship issue for female cancer survivors. Oncologist. 2014;19(2):202.
12. Roberts K, Chong T, Hollands E, Tan J, Kader Ali Mohan GR, Cohen PA. Screening for sexual health concerns in survivors of gynecological cancer. Support Care Cancer. 2020;28(2):599–605.
13. Hafner LB, Harterenbach EM, Carter J, Rash JK, Kushner DM. Maintaining sexual health throughout gynecologic cancer survivorship: a comprehensive review and clinical guide. Gynecol Oncol. 2016;140(2):359–68.
14. Carr SV. Psychosocial health in gynecologic cancer. Int J Gynecol Obstet. 2015;131:159–63.
15. Mutsch J, Friedrich M, Leuteritz K, Sender A, Geue K, Hilbert A, Stöbel-Richter Y. Sexuality and cancer in adolescents and young adults: a comparison between reproductive cancer patients and patients with non-reproductive cancer. BMC Cancer. 2019;19(1):828.
16. Bober SL, Recklitis CJ, Michaud AL, Wright AA. Improvement in sexual function after ovarian cancer: effects of sexual therapy and rehabilitation after treatment for ovarian cancer. Cancer. 2018;124(1):176–82.
17. Lee JT, Kuo HY, Huang KG, Lin JR, Chen ML. Diversity of sexual activity and correlates among women with gynecological cancer. Gynecol Oncol. 2020;159(2):503–8.
18. Blake EA, Flink D, Sheeder J, Carruba B, Maroney M, Whitmore G, Guntupalli S. Chemotherapy use is a significant predictor for sexual dysfunction in women with gynecologic cancer. J Cancer Ther. 2017;8(3):321–6.
19. Bober SL, Varela VS. Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol. 2012;30(30):3712–9.
20. Jensen PT, Klee MC, Thranov I, Groenvold M. Validation of a questionnaire for self-assessment of sexual function and vaginal changes after gynecological cancer. Psycho-Oncol: J Psychol, Soc Behav Dimens Cancer. 2004;13(8):577–92.
21. Zebrack BJ, Chersler MA. A psychometric analysis of the Quality of Life Cancer Survivors (QOL-CS) in survivors of childhood cancer. Qual Life Res. 2001;10(4):319–29.
22. van Bruggen M, van Amelsvoort T, Wouters L, Dingemans P, Haan H, Linszen D. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinol. 2009;34(7):989–95.
23. Cancer research center cancer institute of IR. Available from: http://cri.tums.ac.ir/crc/tehran_cancer_registry/ available at 2018.
24. Soleimani MA, Bahrami N, Yaghooobadzeh A, Parker A, HuakChan Y. Sexual distress and sexual function in a sample of Iranian women with gynecologic cancers. Eur J Oncol Nurs. 2018;35:47–53.
25. Hazaerd munro B. Statistical methods for health care research. Vol. 5th edit. 2005; Philadelphia: Lippincott Williams & Wilkins.
26. https://www.who.int/substance_abuse/research_tools/translation/en/.
27. Dinat I, Ghanbari Z, AsghariJafarabadi M. Psychometric properties of the persian language version of the system usability scale. Health Prom Perspect. 2014;4(1):82.
28. Hajizadeh E, Asghari M. Statistical methods and analyses in health and biosciences: a research methodological approach. Tehran: Jahan Daneshgahi Publications; 2011.
29. Rosen R, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D’Agostino R. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.